These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 25132465)

  • 1. Binding isotope effects as a tool for distinguishing hydrophobic and hydrophilic binding sites of HIV-1 RT.
    Krzemińska A; Paneth P; Moliner V; Świderek K
    J Phys Chem B; 2015 Jan; 119(3):917-27. PubMed ID: 25132465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Theoretical studies of HIV-1 reverse transcriptase inhibition.
    Świderek K; Martí S; Moliner V
    Phys Chem Chem Phys; 2012 Sep; 14(36):12614-24. PubMed ID: 22820901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Theoretical studies of energetics and binding isotope effects of binding a triazole-based inhibitor to HIV-1 reverse transcriptase.
    Krzemińska A; Świderek KP; Paneth P
    Phys Chem Chem Phys; 2016 Jan; 18(1):310-7. PubMed ID: 26612030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rational approaches for the design of effective human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitors.
    Ribone SR; Quevedo MA; Madrid M; Briñón MC
    J Chem Inf Model; 2011 Jan; 51(1):130-8. PubMed ID: 21133347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative free energy of binding and binding mode calculations of HIV-1 RT inhibitors based on dock-MM-PB/GS.
    Zhou Z; Madura JD
    Proteins; 2004 Nov; 57(3):493-503. PubMed ID: 15382241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docking of non-nucleoside inhibitors: neotripterifordin and its derivatives to HIV-1 reverse transcriptase.
    Zhou Z; Madrid M; Madura JD
    Proteins; 2002 Dec; 49(4):529-42. PubMed ID: 12402361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bridge water mediates nevirapine binding to wild type and Y181C HIV-1 reverse transcriptase--evidence from molecular dynamics simulations and MM-PBSA calculations.
    Treesuwan W; Hannongbua S
    J Mol Graph Model; 2009; 27(8):921-9. PubMed ID: 19414275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-reverse transcriptase inhibition: inclusion of ligand-induced fit by cross-docking studies.
    Ragno R; Frasca S; Manetti F; Brizzi A; Massa S
    J Med Chem; 2005 Jan; 48(1):200-12. PubMed ID: 15634014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of a bound non-nucleoside RT inhibitor on the dynamics of wild-type and mutant HIV-1 reverse transcriptase.
    Zhou Z; Madrid M; Evanseck JD; Madura JD
    J Am Chem Soc; 2005 Dec; 127(49):17253-60. PubMed ID: 16332074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining docking, molecular dynamics and the linear interaction energy method to predict binding modes and affinities for non-nucleoside inhibitors to HIV-1 reverse transcriptase.
    Carlsson J; Boukharta L; Aqvist J
    J Med Chem; 2008 May; 51(9):2648-56. PubMed ID: 18410085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined approach using ligand efficiency, cross-docking, and antitarget hits for wild-type and drug-resistant Y181C HIV-1 reverse transcriptase.
    García-Sosa AT; Sild S; Takkis K; Maran U
    J Chem Inf Model; 2011 Oct; 51(10):2595-611. PubMed ID: 21875140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding the basis of resistance in the irksome Lys103Asn HIV-1 reverse transcriptase mutant through targeted molecular dynamics simulations.
    Rodríguez-Barrios F; Gago F
    J Am Chem Soc; 2004 Dec; 126(47):15386-7. PubMed ID: 15563158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conformational Plasticity of the NNRTI-Binding Pocket in HIV-1 Reverse Transcriptase: A Fluorine Nuclear Magnetic Resonance Study.
    Sharaf NG; Ishima R; Gronenborn AM
    Biochemistry; 2016 Jul; 55(28):3864-73. PubMed ID: 27163463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 reverse transcriptase connection subdomain mutations involved in resistance to approved non-nucleoside inhibitors.
    Menéndez-Arias L; Betancor G; Matamoros T
    Antiviral Res; 2011 Nov; 92(2):139-49. PubMed ID: 21896288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel piperidinylamino-diarylpyrimidine derivatives with dual structural conformations as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Chen X; Liu X; Meng Q; Wang D; Liu H; De Clercq E; Pannecouque C; Balzarini J; Liu X
    Bioorg Med Chem Lett; 2013 Dec; 23(24):6593-7. PubMed ID: 24239481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase.
    Gao HQ; Boyer PL; Sarafianos SG; Arnold E; Hughes SH
    J Mol Biol; 2000 Jul; 300(2):403-18. PubMed ID: 10873473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Theoretical studies on the molecular basis of HIV-1RT/NNRTIs interactions.
    Decha P; Intharathep P; Udommaneethanakit T; Sompornpisut P; Hannongbua S; Wolschann P; Parasuk V
    J Enzyme Inhib Med Chem; 2011 Feb; 26(1):29-36. PubMed ID: 20583854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unconventional plasticity of HIV-1 reverse transcriptase: how inhibitors could open a connection "gate" between allosteric and catalytic sites.
    Bellucci L; Angeli L; Tafi A; Radi M; Botta M
    J Chem Inf Model; 2013 Dec; 53(12):3117-22. PubMed ID: 24256065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular dynamics and Monte Carlo simulations for protein-ligand binding and inhibitor design.
    Cole DJ; Tirado-Rives J; Jorgensen WL
    Biochim Biophys Acta; 2015 May; 1850(5):966-971. PubMed ID: 25196360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pharmacophore docking algorithm and its application to the cross-docking of 18 HIV-NNRTI's in their binding pockets.
    Daeyaert F; de Jonge M; Heeres J; Koymans L; Lewi P; Vinkers MH; Janssen PA
    Proteins; 2004 Feb; 54(3):526-33. PubMed ID: 14748000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.